Timothy Kamaldinov1, Josh Erndt-Marino1,2,3, Michael Levin3, David L Kaplan2,3, Mariah S Hahn1. 1. Department of Biomedical Engineering, Rensselaer Polytechnic Institute, Troy, New York. 2. Department of Biomedical Engineering, Tufts University, Medford, Massachusetts. 3. Allen Discovery Center at Tufts University, Department of Biology, Tufts University, Medford, Massachusetts.
Abstract
Background: Human mesenchymal stem cells (hMSCs) are utilized preclinically and clinically as a candidate cell therapy for a wide range of inflammatory and degenerative diseases. Despite promising results in early clinical trials, consistent outcomes with hMSC-based therapies have proven elusive in many of these applications. In this work, we attempt to address this limitation through the design of a stem cell therapy to enrich hMSCs for desired electrical and ionic properties with enhanced stemness and immunomodulatory/regenerative capacity. Materials and Methods: In this study, we sought to develop initial protocols to achieve electrically enriched hMSCs (EE-hMSCs) with distinct electrical states and assess the potential relationship with respect to hMSC state and function. We sorted hMSCs based on fluorescence intensity of tetramethylrhodamine ethyl ester (TMRE) and investigated phenotypic differences between the sorted populations. Results: Subpopulations of EE-hMSCs exhibit differential expression of genes associated with senescence, stemness, immunomodulation, and autophagy. EE-hMSCs with low levels of TMRE, indicative of depolarized membrane potential, have reduced mRNA expression of senescence-associated markers, and increased mRNA expression of autophagy and immunomodulatory markers relative to EE-hMSCs with high levels of TMRE (hyperpolarized). Conclusions : This work suggests that the utilization of EE-hMSCs may provide a novel strategy for cell therapies, enabling live cell enrichment for distinct phenotypes that can be exploited for different therapeutic outcomes. Copyright 2020, Mary Ann Liebert, Inc., publishers.
Background: Human mesenchymal stem cells (hMSCs) are utilized preclinically and clinically as a candidate cell therapy for a wide range of inflammatory and degenerative diseases. Despite promising results in early clinical trials, consistent outcomes with hMSC-based therapies have proven elusive in many of these applications. In this work, we attempt to address this limitation through the design of a stem cell therapy to enrich hMSCs for desired electrical and ionic properties with enhanced stemness and immunomodulatory/regenerative capacity. Materials and Methods: In this study, we sought to develop initial protocols to achieve electrically enriched hMSCs (EE-hMSCs) with distinct electrical states and assess the potential relationship with respect to hMSC state and function. We sorted hMSCs based on fluorescence intensity of tetramethylrhodamine ethyl ester (TMRE) and investigated phenotypic differences between the sorted populations. Results: Subpopulations of EE-hMSCs exhibit differential expression of genes associated with senescence, stemness, immunomodulation, and autophagy. EE-hMSCs with low levels of TMRE, indicative of depolarized membrane potential, have reduced mRNA expression of senescence-associated markers, and increased mRNA expression of autophagy and immunomodulatory markers relative to EE-hMSCs with high levels of TMRE (hyperpolarized). Conclusions : This work suggests that the utilization of EE-hMSCs may provide a novel strategy for cell therapies, enabling live cell enrichment for distinct phenotypes that can be exploited for different therapeutic outcomes. Copyright 2020, Mary Ann Liebert, Inc., publishers.
Authors: Julia Matthias; Julia Maul; Rebecca Noster; Hanna Meinl; Ying-Yin Chao; Heiko Gerstenberg; Florian Jeschke; Gilles Gasparoni; Anna Welle; Jörn Walter; Karl Nordström; Klaus Eberhardt; Dennis Renisch; Sainitin Donakonda; Percy Knolle; Dominik Soll; Stephan Grabbe; Natalie Garzorz-Stark; Kilian Eyerich; Tilo Biedermann; Dirk Baumjohann; Christina E Zielinski Journal: Sci Transl Med Date: 2019-02-20 Impact factor: 17.956
Authors: Joshua M Hare; Jay H Traverse; Timothy D Henry; Nabil Dib; Robert K Strumpf; Steven P Schulman; Gary Gerstenblith; Anthony N DeMaria; Ali E Denktas; Roger S Gammon; James B Hermiller; Mark A Reisman; Gary L Schaer; Warren Sherman Journal: J Am Coll Cardiol Date: 2009-12-08 Impact factor: 24.094
Authors: Stefan M Schieke; Mingchao Ma; Liu Cao; J Philip McCoy; Chengyu Liu; Nancy F Hensel; A John Barrett; Manfred Boehm; Toren Finkel Journal: J Biol Chem Date: 2008-08-18 Impact factor: 5.157
Authors: Madhusudhanan Sukumar; Jie Liu; Gautam U Mehta; Shashank J Patel; Rahul Roychoudhuri; Joseph G Crompton; Christopher A Klebanoff; Yun Ji; Peng Li; Zhiya Yu; Greg D Whitehill; David Clever; Robert L Eil; Douglas C Palmer; Suman Mitra; Mahadev Rao; Keyvan Keyvanfar; David S Schrump; Ena Wang; Francesco M Marincola; Luca Gattinoni; Warren J Leonard; Pawel Muranski; Toren Finkel; Nicholas P Restifo Journal: Cell Metab Date: 2015-12-08 Impact factor: 27.287
Authors: Richard J Cuthbert; Peter V Giannoudis; Xiao N Wang; Lindsay Nicholson; David Pawson; Anatole Lubenko; Hiang B Tan; Anne Dickinson; Dennis McGonagle; Elena Jones Journal: PLoS One Date: 2015-03-11 Impact factor: 3.240